Heart Asia. 2012 Jan 01;4(1):16-22. doi: 10.1136/heartasia-2011-010068. eCollection 2012.
Heart Asia
Ahmad Amin, Majid Maleki
PMID: 27326019 PMCID: PMC4898603 DOI: 10.1136/heartasia-2011-010068
Increasing myocardial contractility has long been considered a big help for patients with systolic heart failure, conferring an augmented haemodynamic profile in terms of higher cardiac output, lower cardiac filling pressure and better organ perfusion. Though concerns have been raised over the safety issues regarding the clinical trials of different inotropes in hearts with systolic dysfunction, they still stand as a main therapeutic strategy in many centres dealing with such patients. They must be used as short in duration, low in dose and stopped as early as possible. Evidence-based guidelines have provided clinicians with valuable data for better applying inotropes in heart failure patients. In this paper, the authors address clinical trials with different agents used for increasing cardiac contractility in heart failure patients. Furthermore, the authors focus on recent guidelines on making the most out of inotropes in heart failure patients.
Keywords: Fallot's tetralogy; Inotropic agents; artificial heart; congenital heart disease; coronary artery disease; heart failure; heart failure with normal ejection fraction; phosphodiesterase inhibitors; rejection; risk stratification; transplantation; ventricular tachycardia; β agonists